Regulations.gov document
2025-000966 - Theralogix - Theralogix, OvaNAD - Contains nicotinamide riboside plus…
Other · FDA-2025-S-0024 · posted Oct 8, 2025
Key facts
| Document ID | FDA-2025-S-0024-0891 |
|---|---|
| Title | 2025-000966 - Theralogix - Theralogix, OvaNAD - Contains nicotinamide riboside plus pterostilbene to support optimal NAD production for healthy ovarian function, reproductive health, and overall vitality |
| Document type | Other |
| Subtype | 30 Day Structured Function Claim |
| Agency | FDA |
| Docket | FDA-2025-S-0024 |
| Posted | Oct 8, 2025 |
| Comment period opens | Oct 8, 2025 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: